Last kr354.30 DKK
Change Today -6.10 / -1.69%
Volume 228.5K
GEN On Other Exchanges
As of 11:02 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/14 - kr365.00
52 Week Low
05/20/14 - kr180.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. Its product pipeline includes Ofatumumab, a human monoclonal antibody, which is in Phase IV clinical studies for the treatment of chronic lymphocytic leukemia; Phase III clinical studies to treat follicular lymphoma, diffuse large B-cell lymphoma, and pemphigus vulgaris; Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, and Waldenstrom’s Macroglobulinemia, as well as Daratumumab, a human CD38 monoclonal antibody that is in Phase I/II clinical studies to treat multiple myeloma. The company’s product pipeline also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for the treatment of active thyroid eye disease. In addition, it has approximately ten active pre-clinical pipeline programs, including naked antibodies and bispecific antibodies developed using DuoBody technology and ADC. The company has collaborations with GlaxoSmithKline, Janssen Biotech, Inc. (Janssen), Seattle Genetics, Inc., Roche, and H. Lundbeck A/S; and technology partnerships with Medarex, Novartis, and Janssen. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

176 Employees
Last Reported Date: 11/5/14
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr10.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr4.9M
Compensation as of Fiscal Year 2013.

genmab a/s (GEN) Key Developments

Genmab A/S Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. plans to start a Phase II study of daratumumab in smoldering multiple myeloma. The study (SMM2001) will evaluate three different dose schedules of daratumumab for the treatment of smoldering multiple myeloma. The study is expected to start enrolling patients in 2015. This Phase II study will be a randomized, open-label, multicenter study and will enroll approximately 120 patients with high risk smoldering multiple myeloma. Patients will be randomized to receive one of three dose schedules of daratumumab. The study will be conducted by Janssen Research & Development LLC.

Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

Genmab A/S announced that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. (Janssen) plans to start an additional Phase III study of daratumumab in frontline multiple myeloma. The study (MMY3006) will compare daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTD) to bortezomib, thalidomide and dexamethasone alone as front line treatment for patients who are candidates for stem cell transplantation (SCT). The study is planned to start in second quarter 2015. The first Phase III study in front line multiple myeloma was announced in July and is expected to start towards the end of this year, with the two other Phase III front line studies to start next year. In total today's news is the fifth daratumumab Phase III study to be announced.

Genmab A/S Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

Genmab A/S announced additional data from the interim analysis of the ofatumumab (Arzerra(tm)) Phase III study, PROLONG (OMB112517). The study evaluated ofatumumab maintenance therapy versus no further treatment (observation) in patients with a complete response (CR) or partial response (PR) after 2nd or 3rd line treatment for chronic lymphocytic leukemia (CLL). The improvement in the study's primary endpoint, progression free survival (PFS), met the prespecified statistical significance level for the interim analysis. A total of 474 patients were included in the interim analysis. Patients who received ofatumumab maintenance treatment lived 13.4 months longer without their disease worsening (median PFS) than patients who received no further treatment. Median PFS was 28.6 months for the ofatumumab treatment arm and 15.2 months for the observation arm (Hazard Ratio 0.48; p<0.0001). The amount of time until patients started their next therapy was significantly longer in the ofatumumab treatment arm than in the observation arm (median 38.0 months vs 27.4 months, Hazard Ratio 0.63; p=0.0076). There were no unexpected safety findings. Adverse events occurred in 87% of patients in the ofatumumab treatment arm versus 75% in the observation treatment arm. In the ofatumumab treatment arm, 25% of patients experienced grade 3-4 adverse events compared to 17% in the observation arm. Grade 3-4 infections were 18% in the ofatumumab arm and 13% in the observation arm. The two most common grade 3-4 adverse events were neutropenia (22% in ofatumumab arm vs 9% in observation arm), and pneumonia (7% in ofatumumab arm vs 4% in observation arm). The death rate was similar in both arms (14%).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr354.30 DKK -6.10

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.19 EUR +0.14
Dyax Corp $14.42 USD +0.29
ImmunoGen Inc $5.93 USD +0.03
MorphoSys AG €76.28 EUR -0.484
Seattle Genetics Inc $32.00 USD +0.90
View Industry Companies

Industry Analysis


Industry Average

Valuation GEN Industry Range
Price/Earnings 65.7x
Price/Sales 22.8x
Price/Book 10.0x
Price/Cash Flow 66.6x
TEV/Sales 19.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at